These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8592087)

  • 1. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone.
    Levi-Schaffer F; Nagler A; Slavin S; Knopov V; Pines M
    J Invest Dermatol; 1996 Jan; 106(1):84-8. PubMed ID: 8592087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma.
    Pines M; Snyder D; Yarkoni S; Nagler A
    Biol Blood Marrow Transplant; 2003 Jul; 9(7):417-25. PubMed ID: 12869955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone.
    Pines M; Domb A; Ohana M; Inbar J; Genina O; Alexiev R; Nagler A
    Biochem Pharmacol; 2001 Nov; 62(9):1221-7. PubMed ID: 11705455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone.
    Halevy O; Nagler A; Levi-Schaffer F; Genina O; Pines M
    Biochem Pharmacol; 1996 Oct; 52(7):1057-63. PubMed ID: 8831725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical treatment of cutaneous chronic graft versus host disease with halofuginone: a novel inhibitor of collagen type I synthesis.
    Nagler A; Pines M
    Transplantation; 1999 Dec; 68(11):1806-9. PubMed ID: 10609960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts.
    McGaha TL; Phelps RG; Spiera H; Bona C
    J Invest Dermatol; 2002 Mar; 118(3):461-70. PubMed ID: 11874485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of halofuginone on the development of tight skin (TSK) syndrome.
    McGaha T; Kodera T; Phelps R; Spiera H; Pines M; Bona C
    Autoimmunity; 2002 Jul; 35(4):277-82. PubMed ID: 12482197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism.
    McGaha TL; Kodera T; Spiera H; Stan AC; Pines M; Bona CA
    Arthritis Rheum; 2002 Oct; 46(10):2748-61. PubMed ID: 12384935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis.
    Pines M; Knopov V; Genina O; Lavelin I; Nagler A
    J Hepatol; 1997 Aug; 27(2):391-8. PubMed ID: 9288615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Halofuginone: a novel antifibrotic therapy.
    Pines M; Nagler A
    Gen Pharmacol; 1998 Apr; 30(4):445-50. PubMed ID: 9522159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Halofugine prevents cutaneous graft versus host disease by suppression of Th17 differentiation.
    Cheng H; Tian J; Zeng L; Pan B; Li Z; Song G; Chen W; Xu K
    Hematology; 2012 Sep; 17(5):261-7. PubMed ID: 22971531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo.
    Gross DJ; Reibstein I; Weiss L; Slavin S; Dafni H; Neeman M; Pines M; Nagler A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3788-93. PubMed ID: 14506172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Halofuginone: an inhibitor of collagen type I synthesis.
    Granot I; Halevy O; Hurwitz S; Pines M
    Biochim Biophys Acta; 1993 Feb; 1156(2):107-12. PubMed ID: 8427869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Halofuginone--an inhibitor of collagen type I synthesis--prevents postoperative formation of abdominal adhesions.
    Nagler A; Rivkind AI; Raphael J; Levi-Schaffer F; Genina O; Lavelin I; Pines M
    Ann Surg; 1998 Apr; 227(4):575-82. PubMed ID: 9563549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention.
    Zion O; Genin O; Kawada N; Yoshizato K; Roffe S; Nagler A; Iovanna JL; Halevy O; Pines M
    Pancreas; 2009 May; 38(4):427-35. PubMed ID: 19188864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth inhibition of prostate cancer xenografts by halofuginone.
    Gavish Z; Pinthus JH; Barak V; Ramon J; Nagler A; Eshhar Z; Pines M
    Prostate; 2002 May; 51(2):73-83. PubMed ID: 11948962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone.
    Halevy O; Genin O; Barzilai-Tutsch H; Pima Y; Levi O; Moshe I; Pines M
    Histol Histopathol; 2013 Feb; 28(2):211-26. PubMed ID: 23275304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in pulmonary fibrosis in vivo by halofuginone.
    Nagler A; Firman N; Feferman R; Cotev S; Pines M; Shoshan S
    Am J Respir Crit Care Med; 1996 Oct; 154(4 Pt 1):1082-6. PubMed ID: 8887611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells.
    Leiba M; Cahalon L; Shimoni A; Lider O; Zanin-Zhorov A; Hecht I; Sela U; Vlodavsky I; Nagler A
    J Leukoc Biol; 2006 Aug; 80(2):399-406. PubMed ID: 16769768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Halofuginone, an inhibitor of collagen synthesis by rat stellate cells, stimulates insulin-like growth factor binding protein-1 synthesis by hepatocytes.
    Gnainsky Y; Spira G; Paizi M; Bruck R; Nagler A; Abu-Amara SN; Geiger B; Genina O; Monsonego-Ornan E; Pines M
    J Hepatol; 2004 Feb; 40(2):269-77. PubMed ID: 14739098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.